EP4698162A1 - Behandlung von hypoparathyroidismus unter verwendung von triphenylcalcilytischen verbindungen - Google Patents

Behandlung von hypoparathyroidismus unter verwendung von triphenylcalcilytischen verbindungen

Info

Publication number
EP4698162A1
EP4698162A1 EP24730090.8A EP24730090A EP4698162A1 EP 4698162 A1 EP4698162 A1 EP 4698162A1 EP 24730090 A EP24730090 A EP 24730090A EP 4698162 A1 EP4698162 A1 EP 4698162A1
Authority
EP
European Patent Office
Prior art keywords
cltx
formula
subject
blood
hypoparathyroidism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24730090.8A
Other languages
English (en)
French (fr)
Inventor
Mary Scott ROBERTS
Michael T. Collins
Iris R. Hartley
Rachel I. Gafni
Kelly B.L. Roszko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Calcilytix Therapeutics Inc
Original Assignee
US Department of Health and Human Services
Calcilytix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Calcilytix Therapeutics Inc filed Critical US Department of Health and Human Services
Publication of EP4698162A1 publication Critical patent/EP4698162A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24730090.8A 2023-04-21 2024-04-19 Behandlung von hypoparathyroidismus unter verwendung von triphenylcalcilytischen verbindungen Pending EP4698162A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363497693P 2023-04-21 2023-04-21
PCT/US2024/025390 WO2024220796A1 (en) 2023-04-21 2024-04-19 Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Publications (1)

Publication Number Publication Date
EP4698162A1 true EP4698162A1 (de) 2026-02-25

Family

ID=91334562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24730090.8A Pending EP4698162A1 (de) 2023-04-21 2024-04-19 Behandlung von hypoparathyroidismus unter verwendung von triphenylcalcilytischen verbindungen

Country Status (3)

Country Link
EP (1) EP4698162A1 (de)
TW (1) TW202506101A (de)
WO (1) WO2024220796A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
US20220288076A1 (en) * 2019-08-13 2022-09-15 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
AU2021343475A1 (en) * 2020-09-18 2023-06-01 Calcilytix Therapeutics, Inc. Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Also Published As

Publication number Publication date
TW202506101A (zh) 2025-02-16
WO2024220796A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
KR100445946B1 (ko) 폐고혈압 치료법
US6645959B1 (en) Method for treating postoperative ileus
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
KR20200115673A (ko) 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
US8481514B2 (en) Therapeutical uses of inecalcitol
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
EP4698162A1 (de) Behandlung von hypoparathyroidismus unter verwendung von triphenylcalcilytischen verbindungen
JP2025148497A (ja) 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
EP0776663B1 (de) Medikament gegen myotonische dystrophie
US6835398B2 (en) Method of administering high-dose, oral magnesium for treatment of chronic pain syndrome of erythromelalgia
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
WO2021198938A1 (ja) 癌または子宮内膜症の患者における癌、子宮内膜症および疼痛の治療のためのジイソプロピルアミン化合物およびヨウ素
EP1253945B1 (de) Ace inhibitor-vasopressin antagonist kombinationen
GB2197198A (en) Analgesic preparations
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
EP1280555B1 (de) Pharmazeutische zusammenzetzung enthaltend furosemid und conivaptan zur behandlung des kongestiven herzversagens
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
WO2026078027A1 (en) Dosage regimens for camlipixant in treating chronic cough
JP2024503377A (ja) バダデュスタットを使用した治療方法
CN117298111A (zh) 一种酰胺类化合物在制备治疗骨质疏松药物中的应用
Lambert ... Folate-containing oral contraceptive preparations
JPWO2003103703A1 (ja) 骨代謝疾患治療剤
CZ2002729A3 (cs) Pouľití dexrazoxanu, výrobek obsahující dexrazoxan, způsob léčení lupénky a způsob výroby léku
DOMINGO et al. Acute Q fever
JPH05194239A (ja) 卵巣欠落によるのぼせ治療剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR